• TherapeuticsMD's third-quarter 2026 net income from continuing operations rose year over year to $501,000.
• License revenue from continuing operations climbed 61% to $1.3 million, primarily due to a $365,000 IMVEXXY milestone payment from Knight.
• Operating expenses from continuing operations increased 6% to $1.7 million, primarily due to higher legal and professional fees.
• The company continues evaluating strategic alternatives, including a merger, acquisition or asset sale, with no timetable established.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TherapeuticsMD Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611131605BIZWIRE_USPR_____20261113_BW198733) on November 13, 2026, and is solely responsible for the information contained therein.